alemtuzumab + sirolimus + tacrolimus

This is a combination immunosuppressive regimen used primarily in solid organ transplantation, especially kidney transplantation. The regimen typically involves induction therapy with alemtuzumab (a monoclonal antibody targeting CD52 on lymphocytes), followed by maintenance with the mTOR inhibitor sirolimus and the calcineurin inhibitor tacrolimus. The goal is to prevent acute and chronic rejection while minimizing toxicity and side effects associated with long-term immunosuppression[1][2][3]. Alemtuzumab depletes T cells, reducing early immune response; sirolimus inhibits T-cell activation via mTOR blockade; tacrolimus suppresses T-cell activation by inhibiting calcineurin. This combination has been studied for its potential to allow step-wise withdrawal of immunosuppressants or reduced long-term drug burden[3].

Other names

Campath-1H (alemtuzumab) + sirolimus + tacrolimusalemtuzumab/sirolimus/tacrolimus combination